Details

Autor(en) / Beteiligte

• MORENO, M. B
• TITUS, J. A
• COLE, M. S
• YUN TSO, J
• NHAT LE
• PAIK, C. H
• BAKACS, T
• ZACHARCHUK, C. M
• SEGAL, D. M
• WUNDERLICH, J. R

Titel

Bispecific antibodies retarget murine T cell cytotoxicity against syngeneic breast cancer in vitro and in vivo

Ist Teil von

• Cancer Immunology Immunotherapy, 1995-05, Vol.40 (3), p.182-190

Ort / Verlag

Berlin: Springer

Erscheinungsjahr

1995

Quelle

MEDLINE

Beschreibungen/Notizen

• Bispecific antibodies with specificity for CD3 and a tumor antigen can redirect cytolytic T cells to kill tumor targets, regardless of their natural specificity. To assess the clinical potential of bispecific antibodies for treatment of human cancers we have, in the present study, adapted a totally synergeic mouse model to the targeting of mouse T cells against mouse tumors in immunocompetent mice. We show that gp52 of the mouse mammary tumor virus (MTV) can serve as a tumor-specific antigen for redirected cellular cytotoxicity. Chemically crosslinked and genetically engineered bispecific antibodies with specificities for gp52 and murine CD3 epsilon-chain induced activated mouse T cells to specifically lyse mouse mammary tumor cells from cultured lines and primary tumors from C3H-MTV+ mice. Retargeted T cells also blocked the growth of mammary tumors in vitro as well as their growth in syngeneic mice. These findings identify murine MTV-induced mammary adenocarcinomas as a solid-tumor, animal model for retargeting T cells with bispecific antibodies against syngeneic breast cancer.